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Short Introduction 
The initiation of insulin action first involves its binding 
to a specific receptor on the cell membrane and this is followed 
by the stimulation of glucose transport and intracellular glucose 
metabolism. Although the acute effects of insulin on glucose 
transport have been well characterized, the effects of more chronic 
exposure to insulin are less well defined. These effects are of 
general interest in understanding insulin physiology, and assume 
clinical importance in understanding what role hyperinsulinemia 
plays in the insulin resistance associated with obesity (1-4), 
maturity-onset diabetes (5-11), uremia (12-14), acidosis (15), and 
other insulin resistant states. 
Recently, strong evidence has been provided to support the 
concept that prolonged insulin exposure, both in vitro (15-18) 
and in vivo (16-20), is capable of leading to a decrease in the 
number of insulin receptor sites on the cell surface. However, the 
metabolic consequence of this decrease in receptor binding has yet 
to be established. 
Much less is known about the effect of prolonged in vitro or 
in vivo hyperinsulinemia on glucose transport and metabolism. Olefsk} 
et. al. have documented an increase in 2-deoxyglucose (2-DOG ) transport 
by adipocytes obtained from rats chronically made hyperinsulinemic 
with a 14 day protocol of insulin injections (21, 22). Employing 
the insulin clamp technique in man, Soman and DeFronzo have demon¬ 
strated a small but significant increase in overall glucose metab¬ 
olism following 3-5 hours of hyperinsulinemia (20). However, other 
studies have failed to document an increase in cellular glucose 
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transport following a prolonged in vivo (19) or in vitro (18) 
exposure to insulin. Instead, these studies (18, 19) found a 
decrease in tissue sensitivity to insulin and have attributed 
this to the decrease in receptor number which followed prolonged 
insulin exposure (18, 19). 
The present study was undertaken: 1) to examine the rate 
of overall in vivo glucose metabolism during sustained, physiologic 
hyperinsulinemia and 2) to evaluate glucose transport by rat soleus 
muscle following prolonged in vivo hyperinsulinemia. To accomplish 
this goal, the euglycemic insulin clamp technique (23) was approp¬ 
riately modified to allow study of the unanaesthetized rat. With 
this technique a steady-state plateau of hyperinsulinemia can be 
achieved while maintaining the plasma glucose concentration con¬ 
stant at the basal level. 
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Introduction 
I. Glucose Transport 
Following the binding of insulin to a cell surface receptor, 
glucose transport is activated and this represents the first step 
in the cellular metabolism of glucose. Stimulation of glucose 
transport is extremely sensitive to insulin and occurs at hormone 
concentrations well within the physiologic range. Most importantly, 
insulin-stimulated glucose metabolism in vivo appears to represent 
a primary effect on glucose transport rather than a stimulation of 
intracellular glucose metabolism (24, 25). 
Early studies of glucose transport were performed by examining 
glucose disappearance from the media (26) or by the chemical deter¬ 
mination of non-metabolized glucose analogues taken up by the cell 
(27, 28). More recently, radioactively-labelled non-metabolized 
glucose analogues, including 3-O-methylglucose (3-0-MG) and 2-deoxy- 
glucose (2-DOG), have been employed to study cellular glucose 
transport. 3-0-MG is transported into the cell but not further 
metabolized (27). However, there is also a significant efflux 
of 3-0-MG from the cell and uptake actually represents the sum of 
influx and efflux. The intracellular accumulation of 3-0-MG proceeds 
until a steady-state equilibrium is reached. Thus, the uptake of 
3-0-MG reflects glucose transport only if initial rates of uptake 
are measured, i.e., before significant intracellular accumulation 
of 3-0-MG has occurred and the rate of efflux becomes quantitatively 
important. Consequently, special methodology (29) is necessary 
to analyze the initial rapid rates of 3-0-MG uptake and this feature 

_ 4 - 
makes the study of 3-OMG transport difficult. In contrast to 3-0-MG, 
2-deoxyglucose (2-DOG) is transported into the cell and phosphory- 
lated by the enzyme hexokinase (28). However, 2-deoxyglucose- 
phosphate (2-DOG-P) is not further metabolized (28). Under con¬ 
ditions where transport of 2-DOG is rate-limiting and phosphory¬ 
lation is rapid, little free 2-DOG accumulates within the cell 
and there is no significant efflux of 2-DOG from the cell. Thus, 
uptake of 2-DOG into the cell is linear with time and this feature 
greatly facilitates study of glucose transport with this analogue. 
Early studies by Kipnis and Cori (28) demonstrated that 2-DOG 
was transported by rat diaphragm and that glucose and 2-DOG had 
similar affinities for the transport system. Furthermore, uptake 
was found to be linear even under conditions of high rates of 
2-DOG transport (28). All intracellular deoxyglucose was present 
as the phosphorylated derivative indicating that the hexokinose 
enzyme was not rate-limiting. Thus, 2-DOG uptake appeared to pro¬ 
vide a good measure of glucose transport into the cell. 
Most of the initial studies on glucose transport employed rat 
diaphragm. However, diaphragm is a constantly contracting muscle 
and subsequent studies have shown that it does not reflect typical 
skeletal muscle (30). Therefore, more recent studies have employed 
soleus muscle which is composed mainly of slow-twitch red fibers 
and is more representative of whole body skeletal muscle mass. 
The soleus muscle can be isolated as an intact preparation without 
damage to the muscle fibers (26). Uptake of 2-DOG has been shown 
to be linear at a 2-DOG concentration of 0.5 mM for prolonged 
periods of time (31). Transport of 2-DOG in soleus muscle is 
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thought to be rate-limiting since: 1) the Km for hexokinase is 
lOx less than for transport, and 2) intracellular concentrations 
of free 2-DOG are very small (31). 
II. Insulin-Stimulated Glucose Transport 
Insulin stimulation of glucose transport is thought to involve 
three steps: 1) insulin binding to specific plasma membrane re¬ 
ceptors, 2) coupling between occupied receptors and glucose 
transport units, and 3) activation of glucose transport units. 
Insulin Binding 
The importance of insulin receptor binding in the activation 
of cellular glucose transport was first suggested by the observa¬ 
tion that when adipocytes were treated with trypsin insulin binding 
was diminished and this was parallelled by a decrease in cellular 
glucose transport (32, 33). More recently, the relationship between 
insulin receptor binding and glucose transport activation has been 
examined in adipocytes (34-37) and soleus muscle (31). 
Radioligand binding has been used to define insulin receptors 
on the plasma membrane (38). Such receptors are assumed to be 
125 present if the binding of I-insulin can be shown to be 1) sat¬ 
urable and 2) competitively inhibited by the addition of unlabelled 
insulin. Using such radioligand binding systems several investi¬ 
gators have attempted to examine the relationship between insulin 
binding and insulin-mediated activation of the glucose transport 
system (31, 34-37). Insulin stimulation of glucose transport has 
been shown throughout the range of physiological insulin concen- 
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trations (31, 34-37). However, half-maximal stimulation of glu¬ 
cose transport occurs at insulin concentrations where only 5% 
receptor occupancy is present, and maximal stimulation occurs 
where approximately 20% of receptors are bound by insulin (31, 
34-37). The term spare receptors (31, 34-37) has been used to 
describe the remaining 80% of the receptors beyond those necessary 
to elicit a maximal biologic response. 
Interpretation of spare receptors is complicated by the early 
observation that receptor binding affinity is not uniform but 
decreases with receptor occupancy (38, 39). This observation is 
compatible with the existence of 1) two or more distinct popula¬ 
tions of receptors with different fixed binding affinities or 2) 
a uniform population of receptors which display site to site inter¬ 
actions with modification of binding affinity as receptor occupancy 
changes. Distinct receptor populations might suggest that high 
affinity receptors are physiologically active while low affinity 
receptors are inactive. However, Demeyts et. al. (39) demon¬ 
strated the conversion of high affinity to low affinity sites when 
receptor occupancy was increased. These experiments provided 
evidence that a uniform population of binding sites exists and is 
capable of negative cooperativity in the binding of insulin. Thus, 
insulin receptors may represent a uniform population of sites 
that are physiologically equivalent. It is postulated that 
occupancy of an equal number of any random insulin receptors will 
produce an equivalent response. 
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Glucose Transport Activation 
The mechanism of insulin stimulation of glucose transport has 
been examined by Olefsky et. al. (34-37) employing 2-DOG uptake 
in isolated rat adipocytes. Transport is a function of extracellular 
2-DOG concentration. By analogy to an enzymatic model, insulin 
activation can be viewed as representing an increase in Vmax for 
the system rather than an alteration in the Km or affinity for 
2-DOG (34). Based on similar activation energies, for basal and 
insulin-stimulated transport, the insulin induced increase in Vmax 
may represent a recruitment of new transport units rather than 
enhanced mobility of already active units (34). 
Recently, cytochalasin-B binding has been employed to study 
glucose transport activation by insulin (40, 41). Cytochalasin-B 
binding sites are thought to be closely related to the glucose 
transport system (40, 41) since: 1) low concentrations of cyto¬ 
chalasin-B inhibit glucose transport and 2) the effectiveness of 
sugars in inhibiting cytochalasin-B binding is stereo-specific and 
related to their affinity for the glucose transport system. An 
increase in plasma membrane cytochalasin-B binding and a stoichio¬ 
metric decrease in microsomal membrane cytochalasin-B binding are 
correlated with insulin activation of glucose transport i.in rat 
adipocytes (41, 42). Thus, these results suggest that insulin 
activation of glucose transport may involve the recruitment of new 
transport units into the plasma membrane from an intracellular 
microsomal pool. 
i- 
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III. Effects of Prolonged Insulin Exposure 
The acute stimulating effects of insulin on glucose transport, 
glycolysis, and glycogen synthesis have been well studied in vitro 
in adipocytes (34-37) and skeletal muscle (31). Similarly, the 
acute stimulation of glucose utilization by peripheral tissues has 
recently been examined in vivo during experimental hyperinsulinemia 
in man (23). In contrast, the effects of prolonged in vitro or 
in vivo insulin exposure on glucose metabolism have not been well 
defined. These effects are important not only in understanding 
the physiology of insulin, but also in understanding what role 
chronic hyperinsulinemia plays in insulin resistant states. 
Difficulty in studying the effects of prolonged insulin ex¬ 
posure has stemmed from problems 1) in maintaining tissue viable 
in vitro for extended periods of time and 2) in developing a 
suitable model of hyperinsulinemia which maintains the plasma 
glucose concentration constant. Although improved tissue culture 
techniques have made it possible to study the effects of chronic 
in vitro insulin exposure, the study of chronic in vivo hyperin¬ 
sulinemia has proven difficult. Experimental models of chronic 
hyperinsulinemia have been developed in the rat (19, 21, 22) but 
have been associated with wide fluctuations in plasma glucose 
levels. Development of the euglycemic insulin clamp technique 
(23) has been important in the study of hyperinsulinemia in man, 
although studies to date have examined hyperinsulinemia for only 
3-5 hour periods (20). 
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Hyperinsulinemia and decreased receptor binding 
Interest in the effect of changes in circulating insulin 
levels on its own receptor were first raised by the frequently 
observed inverse correlation between fasting plasma insulin con¬ 
centrations and insulin receptor binding. This inverse correl¬ 
ation has been demonstrated in normal man (5), in subjects with 
obesity (1-4), maturity-onset diabetes (5, 6) and following fasting 
(1, 43-45) and carbohydrate feeding (1, 43, 46). Similar obser¬ 
vations have been made in animal models of obesity (31, 47-50) 
streptozotocin-induced diabetes (51-54), and following fasting (53- 
55) . 
Both in vitro (16-18) and in vivo (19, 20, 56) experiments have 
established that hyperinsulinemia leads to a decrease in insulin 
receptor binding. Down-regulation of insulin receptors was first 
demonstrated in vitro by Gavin et. al. (16) who found a decrease 
in insulin receptor binding in cultured lymphoblastoid cells fol¬ 
lowing a 5-16 hour exposure to supraphysiologic concentrations (10 mM) 
of insulin (16). This effect was time, concentration, and temp¬ 
erature dependent (16). The decrease in insulin receptor binding 
was due to a decrease in receptor number without any change in 
receptor binding affinity (16). Decreased receptor binding has 
also been demonstrated at more physiologic insulin concentrations 
in cultured rat hepatocytes following a 16 hour exposure to 1 nM 
of insulin (17). Down-regulation of insulin receptor binding in 
vitro has also been shown in rat adipocytes following exposure to 
pharmacologic doses of insulin (10.5 nM)5 but not to physiologic 
doses (18). 
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Down-regulation in vivo has also been observed following ex¬ 
perimental hyperinsulinemia. Rat adipocytes show a 40% decrease 
in insulin receptor binding in animals maintained on a chronic 14 
day regime of NPH insulin injections (19). The plasma insulin 
level was reported to be 65 ± 5 '/HJ/ml 12 hours after the last dose 
of NPH insulin (19). Thus, it is likely that much higher plasma 
insulin levels, in excess of 150-200 _-/CrU/ml were reached during 
this experiment. The interpretation of these changes is also some¬ 
what obscured by the large fluctuations in plasma glucose levels 
that occured during this study. Less prolonged exposure to in 
vivo hyperinsulinemia has also been shown to decrease insulin 
receptor binding in man (20, 56). Sustained hyperinsulinemia of 
3-5 hours duration produced by the euglycemic insulin clamp technique 
resulted in a 25-30% decrease in monocyte binding at insulin levels 
of 31 ± 2 ^U/ml (20). A greater decrease (40%) in insulin re¬ 
ceptor binding was observed with plasma insulin levels of 102 ± 6 
^/t<U/ml (20). Hyperinsulinemia produced by the quadruple infusion 
technique (insulin, glucose, epinephrine, and propranalol) also 
resulted in decreased insulin receptor binding with steady-state 
insulin levels of 108-118 y^U/ml (56). When a lesser degree of 
hyperinsulinemia (27-31 was created with concomitant hyper¬ 
glycemia, a decrease in insulin receptor binding was also observed 
after 5 hours (56). This was attributed to a decrease in receptor 
binding affinity for insulin (56). 
Thus, the phenomenon of down-regulation (38, 57, 58) has been 
demonstrated for insulin receptors following both in vitro and in 
vivo exposure to insulin, both in man and animals. Most importantly, 
- 
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the phenomenon of down-regulation has been demonstrated with 
insulin concentrations in vivo which are well within the physiologic 
range and which have commonly been observed in the post-prandial 
state and in insulin resistant states. As previously discussed, 
present receptor theory would predict that a decrease in insulin- 
mediated glucose metabolism should accompany a decrease in insulin 
receptor binding. More specifically, one would expect a decrease 
in "sensitivity" (59) to insulin, i.e., an increase in the concen¬ 
tration of insulin required to elicit half-maximal stimulation of 
the full insulin response. In fact, any concentration of insulin 
below that which achieves a maximal effect would be expected to 
have a decreased effect. In contrast, one would not expect a 
decrease in "responsiveness" (59) to insulin, i.e,, a change in the 
maximal biological response that can be achieved at any concentration 
of hormone, because at increasing concentrations of insulin, binding 
of spare receptors should achieve a sufficient receptor occupancy 
to elicit the maximal biological response. Thus, a rightward shift 
in the dose response curve with normalization at maximally effective 
insulin concentrations is the predicted consequence of a decrease in 
insulin receptor binding. 
Hyperinsulinemia and glucose metabolism 
Definition of the effects of prolonged insulin exposure on 
glucose metabolism requires the study of tissues active in glucose 
metabolism following either in vitro or in vivo exposure to insulin. 
Livingston et. al. studied rat adipocytes following a 17 hour in 
vitro exposure to 3.5-10.5 nM of insulin (18). This in vitro 
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exposure to supra-physiologic doses of insulin produced a rightward 
shift in the insulin dose response curve, but no change in either 
basal or maximal insulin-stimulated rates of glucose transport. 
Similar findings have been reported by Olefsky et. al. who 
studied 2-DOG transport in adipocytes isolated from rats made 
chronically hyperinsulinemic in vivo with a 14 day regime of twice 
daily NPH insulin injections (19). However, subsequent studies 
from the same lab have demonstrated a significant increase in both 
basal and maximal insulin-stimulated 2-DOG transport in rats sim¬ 
ilarly treated (21, 22). Although these results are inconsistent, 
the latter data suggest that chronic in vivo hyperinsulinemia may 
increase cellular glucose transport. However, the failure to 
maintain euglycemia in these animals complicates the interpret¬ 
ation of these results. This model of hyperinsulinemia (19, 21, 
22) in fact represents the combined effects of both prolonged 
insulin exposure and changes in plasma glucose concentration. 
Despite free access to 5% glucose drinking water and sugar cubes, 
the hyperinsulinemic animals were markedly hypoglycemic compared 
to controls which were both hyperglycemic (plasma glucose = 152 ± 5 
mg/dl) and hyperinsulinemic (plasma insulin = 29 ± 3y*U/ml). Plasma 
glucose concentration was measured only at the time of sacrifice 
which was 12 hours after the last insulin dose. The results 
indicate that many, if not all, of the hyperinsulinemic rats 
were frankly hypoglycemic throughout a significant period of the 
2 week study. The authors attempted to negate the effects of 
hypoglycemia by treating another group of rats with injections of 
20% glucose given 4 times daily to prevent hypoglycemia (19, 21, 22), 
However, these animals were subject to large fluctuations in plasma 
- 
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glucose during the day with periods of marked hyperglycemia. Al¬ 
though these authors have concluded that chronic in vivo hyper- 
insulinemia results in an increase in cellular glucose transport 
(21, 22), significant changes in plasma glucose concentration were 
clearly present and it is also likely that changes in counter- 
regulatory hormones also occurred. Both of these factors could 
have potentially contributed to the findings in this model. 
The development of the euglycemic insulin clamp technique 
(23) has made it possible to study the effects of prolonged hyper- 
insulinemia on in vivo glucose metabolism, while maintaining plasma 
glucose concentration constant at the basal level and avoiding the 
release of counter-regulatory hormones (20). With this technique, 
a prime-continuous insulin infusion is administered intravenously 
to rapidly achieve steady-state hyperinsulinemia while euglycemia 
is maintained by a variable glucose infusion based on a negative 
feed back principle (23). Since hyperinsulinemia suppressed hepatic 
glucose production and since urinary glucose loss is negligible 
under these conditions (23), the glucose infusion rate required to 
maintain euglycemia represents a measure of the amount of total in 
vivo insulin-stimulated glucose metabolism. Using this technique, 
Soman and DeFronzo (20) have demonstrated a small but significant 
increase in in vivo glucose metabolism during the 3-5 hour period 
of hyperinsulinemia at two different plasma insulin levels (30 and 
100 U/ml). The increase in insulin-stimulated glucose metab¬ 
olism occurred despite a 30-40% decrease in insulin receptor binding 
to circulating monocytes (20). However, since the monocyte is 
not a target tissue for insulin-mediated glucose metabolism, studies 
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examining changes in cellular glucose transport or metabolism 
could not be performed. Similar results have been reported using 
the quadruple infusion technique in man (56), but again changes in 
cellular glucose transport and metabolism could not be evaluated, 
since circulating erythrocytes were employed and this tissue is 
also not a target tissue for insulin-mediated glucose metabolism. 
V. Clinical significance of hyperinsulinemia 
Interest in the effects of chronic in vivo hyperinsulinemia 
on glucose metabolism has been prompted by a clinical interest in 
what role hyperinsulinemia might have in insulin resistant states. 
An inverse relationship between fasting plasma insulin concentration 
and insulin receptor binding, and a positive correlation between 
decreased insulin binding and decreased insulin action in vivo, 
have been observed in insulin resistant states including obesity 
(1-3) and maturity - onset diabetes (5, 6) in man. 
The data discussed above provide strong evidence that hyper¬ 
insulinemia per se leads to a decrease in insulin receptor binding 
(16-20, 56) and suggest that hyperinsulinemia may also play an 
important role in the decrease in insulin receptor binding observed 
in insulin resistant states. However, the metabolic consequence of 
decreased receptor binding has not been directly established. De¬ 
creased receptor binding has been shown to correlate with decreased 
insulin sensitivity in vivo in obese man (1, 2, 3). In obese 
rodents, a decrease in receptor binding has also been correlated 
with a decrease in insulin sensitivity in vitro in adipocytes (50) 
and skeletal muscle (31). However, in addition obese animals also 
demonstrate a decrease in tissue responsiveness to insulin both 
- 
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in adipocytes (50, 60) and in skeletal muscle (31). Although 
hyperinsulinemia may be responsible for the receptor-mediated 
decrease in insulin sensitivity, what role, if any, hyperinsulin- 
emia plays in the decreased tissue responsiveness to insulin 
remains to be defined. 
The relationship between insulin resistance, hyperinsulinemia, 
and decreased receptor binding in maturity - onset diabetes is even 
less clear. Although a decrease in insulin receptor binding has 
been correlated with a decrease in in vivo insulin sensitivity (5), 
those diabetics did not manifest fasting hyperinsulinemia. Further¬ 
more, other studies have failed to correlate decreased receptor 
binding with decreased in vivo insulin sensitivity (6). Thus, 
what role hyperinsulinemia plays,and the mechanism of insulin 
resistance, in maturity-onset diabetes is unclear. 
Streptozotocin-treated diabetic rats are hypoinsulinemic and 
demonstrate an increase in both insulin receptor binding and in 
vitro tissue sensitivity to insulin (51, 52, 54). However, in 
addition, adipocytes from these animals show a decrease in both 
basal and maximal insulin-stimulated glucose transport (51, 52) 
and glucose oxidation (51). In contrast, soleus muscles from 
similar animals showed only an increase in tissue sensitivity 
to insulin (54). At least in adipocytes, these hypoinsulinemic 
animals appear to have a defect in the glucose transport system 
per se. Similar results have been observed in hypoinsulinemic 
animals following prolonged fasting (53-55). It has not yet been 
established whether these "post-receptor" defects are a direct 
effect, a secondary effect, or independent of decreased circulating 
insulin levels. Although other explanations are possible, these 
- 
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findings are compatible with a decrease in circulating insulin 
levels per se leading to a decrease in cellular glucose metabolism. 
In summary, although the acute effects of insulin have been 
well studied, the effects of prolonged insulin exposure on glucose 
metabolism are not well defined. The effects of chronic hyperin- 
sulinemia are of importance not only in the understanding of 
insulin physiology, but also in the understanding of insulin re¬ 
sistance in hyperinsulinemic states. 

17 
Methods 
Animals 
Fifty-five male Sprague Dawley rats (156 ± 3 grams body weight) 
were maintained in a constant temperature room with a 12 hour light 
cycle. All studies were performed in the post-absorptive state 
after a 12-14 hour overnight fast. Animals were allowed free 
access to drinking water until the start of the study. 
Four days prior to study, chronic indwelling catheters (PE-50 
polyethylene tubing) were inserted into the jugular vein and carotid 
artery for infusions and withdrawal of blood samples respectively. 
Animals were anesthetized withNembutol (0,08cc/100 grams body 
weight, IP) and a vertical midline incision was made to expose 
the right internal jugular vein and carotid artery. The venous 
catheter was inserted into the jugular vein and passed via the 
superior vena cava into the right atrium. The carotid artery 
catheter was passed to the origin of the right brachiocephalic 
artery. The catheters were secured in place with 4-0 silk and 
the distal ends were tunnelled subcutaneously to the dorsum of 
the neck where they exited via a skin incision. The animals recov¬ 
ered quickly after the surgical procedure and were eating and 
drinking within 12 hours. Catheters were flushed daily with 0.2 cc 
of heparinized saline (0.9% saline + 100 U/ml heparin) to maintain 
patency. 
All animals were studied 4-5 days following catheter placement. 
At the time of study, they were restrained in a plexiglass cage 
which allowed them to rest comfortably but limited them from moving 
' 
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about. The catheters exited through a hole in the top of the 
cage. 
Euglycemic Insulin Clamp 
To produce sustained physiologic elevations of plasma insulin, 
a priming infusion of insulin was administered during the first 8 
minutes and this was followed by a continuous insulin infusion at 
the rate of 1.75 y^U/gram body weight per minute (Table 1). The 
continuous insulin infusion was maintained throughout the three 
hour study period and raised steady-state levels by approximately 
SOy^U/ml above fasting plasma insulin. The insulin infusion was 
prepared from regular crystalline porcine insulin (Lilly Co., 
Indianapolis, Ind.) in 0.9% saline; 300 mg of albumin were added 
to each 100 ml of normal saline to prevent adherence of the insulin 
to the glassware and plastic tubing. 
During the 3 hour period of hyperinsulinemia, the plasma 
glucose concentration was maintained constant at the basal fasting 
glucose level by the infusion of a 5% glucose solution. The glucose 
infusion is started 4 minutes following initiation of the insulin 
infusion. The initial glucose infusion was empirically set at 
7 y^g/gram body weight per minute. At 8 minutes the glucose 
infusion rate was increased to 10 /^g/g*min., and at 11 minutes 
to 14 ^g/g • min. Subsequent alterations in the glucose infusion 
rate were based on determinations of arterial plasma glucose drawn 
at 10-15 minute intervals. The first glucose determination was 
obtained 15 minutes after initiation of insulin infusion. In the 
initial experiments, the glucose infusion rate was adjusted using 
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TABLE 1. The Prime Continuous Insulin Infusion 
Employed During Euglycemic Insulin Clamp 
Time (Min.) Insulin Infusion Rate (y^U/g Body Wt. Min.) 
0-2 3.36 
2-8 2.40 
8-180 1.75 
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a negative feed back formula as previously described by DeFronzo 
et. al. (23). This formula takes into account changes in the rate 
of glucose metabolism as well as changes in the size of the glucose 
pool. After the first few studies all changes in the glucose 
infusion rate were made empirically based on experience gained 
from the initial studies. 
Plasma insulin concentration was determined in the basal 
state and at 60, 120, and 180 minutes during insulin infusion. 
Plasma epinephrine was determined at 180 minutes. 
Twenty-three rats served as a control group. These animals 
were treated similarly to the above group except that they received 
a 3 hour infusion of normal saline instead of the glucose-insulin 
infusions. Blood samples for insulin and glucose determinations 
were obtained as described above. 
Computations 
Glucose Metabolism ( M ). Under steady-state conditions of 
euglycemia, the glucose infusion rate (INF) must be equal to the 
amount of glucose taken up and metabolized by all tissues and pro¬ 
vides a measure of insulin-stimulated glucose metabolism. This 
assumes that hepatic glucose production (HGP) is complete suppressed. 
To the extent that HGP is not suppressed, the rate of endogenous 
glucose production must be added to the glucose infusion rate to de¬ 
termine the actual rate of tissue glucose metabolism. In the present 
study HGP was not directly determined. These studies are presently 
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being performed and until completed it should be noted that the 
rates of glucose metabolism presented in Table 3 may be a slight 
underestimate of the true rate of glucose metabolism. 
During the insulin clamp study, small changes in plasma glucose 
do occur. These changes represent additions of glucose to, or sub¬ 
tractions from, the glucose space caused by a change in the rate of 
tissue glucose metabolism. Thus, the infusion rate (INF) must be 
corrected by a space correction (SC) to arrive at the true rate of 
glucose metabolism ( M ). Therefore, 
M = INF - SC 
The space correction is given by the formula: 
SC = (G2-G-^) x 10 x (0.19 x body weight) 
(T2~Ti) x body weight 
Where (G^-G^) is the change in plasma glucose in mg/dl, (G^-G].) x ^ 
is the change in mg/1, (0.19 x body weight) was used to approximate 
the glucose space, and (T2 - T^) is the time interval. In this study 
glucose metabolism ( M ) was calculated for 40 minute time inter¬ 
vals and in this case the space correction formula reduces to: 
SC = ^-Gp x 0.0475 
Units for SC are expressed as /g/gram body weight per minute of 
glucose added or subtracted. 
The metabolic clearance rate (MCR) for insulin is calculated 
as described previously (23). 
_ insulin infusion rate_ 
increase in plasma insulin above basal 
MCR is expressed in ml/gram body weight per minute when the insulin 
infusion rate is in^U/gram body weight per minute and the increase 
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in steady-state insulin levels above basal is in _/^U/ml. This 
assumes that endogenous insulin secretion remains constant during 
insulin infusion. To the extent that elevation of plasma insulin 
leads to a decrease in basal insulin secretion (23), the metabolic 
clearance rates given in Table 3 may be slightly overestimated. 
Statistical analyses were done by the unpaired student's 
t-test (61). All data are presented as mean ± SE. 
Deoxyglucose Transport 
Following 180 minutes of insulin-glucose or saline infusion 
animals were sacrificed. Nembutol (0.2 cc/100 grams body wt.) 
was administered through the venous catheter and within 10-15 
seconds both legs were removed. Soleus muscle was exposed, tendons 
ligated with 4-0 silk, and excised intact. Muscles were tied 
taught onto stainless steel rings (3/4 inches diameter), rinsed 
with 0.9% saline, and placed in glass incubation vials. Incu¬ 
bations were conducted in a shaking water bath at 20 °C under a 
95% 0^ 5% CO2 atmosphere. 
Muscles were initially preincubated for 15 minutes in a 2 mM 
pyruvate Krebs bicarbonate albumin buffer: Krebs ringer (120 mM 
NaCl, 3 mMKCl, 1,2 mM MgSO^ 2.5 mM CaCl2, 1,2 mM KH^PO^) with 24nM 
NaHCO^ and bovine serum albumin (2 g/100 cc). Following the 15 
minute preincubation period, muscles were removed and the final 
incubation was carried out for 3 hours in Krebs bicarbonate albumin 
buffer (pH 7.4). One muscle from each animal was incubated in 
the absence of insulin, while the other muscle was incubated with 
insulin at one of the following concentrations: 0.5, 0.75, 1.0, 
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5 • 0 , 10.0 mg/ml. 
Following the 3 hour incubation period, glucose transport was 
determined by the addition of 0.2 mM ^C-2-deoxy-D-glucose (1/Ci/ 
incubation vial) (New England Nuclear, Boston, MA) for 15 minutes. 
Muscles were removed and washed 6 times for 5 minutes in 5 cc of 
an ice-cold 0.9% NaCl + 500 mg/lOOcc human serum albumin solution. 
Sutures were then removed, and the tendons were trimmed. The 
muscles were dried at 120°C for 24 hours, weighted, and dissolved 
in 1 ml of 1 N NaOH for 12 hours. Following dilution to 10 ml 
with distilled water, a 1 ml aliquot was taken for counting. 
Analytic Methods 
Plasma glucose determinations were made on 50^/fL samples,ob¬ 
tained from the carotid artery,using the glucose oxidase method 
(Yellow Springs Instruments, Model 23A, Yellow Springs, OH). Plasma 
insulin and epinephrine determinations were performed by Dr. Rosa 
Hendler. Insulin was measured on pooled samples by radioimmun¬ 
oassay (62). Epinephrine was measured on blood samples obtained 
at sacrifice by a radioenzymatic assay (63). ^C-2-D0G radio¬ 
activity in dissolved muscles was determined in duplicate following 
the addition of aquasol (New England Nuclear, Boston, MA) and 
counting with a Packard spectrometer (Packard Instruments, Model 
3320, Palo Alto, CA). ^C-2-D0G uptake is expressed as pmoles of 
2-DOG/mg dry wt of tissue-15 min. 
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Results 
Euglycemic Insulin Clamp 
Basal plasma insulin concentration in the post-absorptive 
state prior to infusion of insulin averaged 23 ± 2 z^U/ml (Table 2). 
The steady-state plasma insulin concentration during the insulin 
clamp study was 55 ± 2 y^U/ml (Table 2). Steady-state levels were 
54 ± 3 y^U/ml at 60 minutes, 55 ± 2 ^U/ml at 120 minutes, and 55 ± 2 
/»U/ml at 180 minutes (Figure 1). The mean increment in plasma 
insulin concentration during the 180 minute study period was 31 ± 2 
U/ml (Table 2). The metabolic clearance rate of insulin was 
0.065 ± 0.007 ml/gram body wt -min. (Table 2). 
Basal arterial plasma glucose was 100 ± 1 mg/dl in the post- 
absorptive state following a 14-16 hour fast, and was maintained 
at 97 ± 2 mg/dl during the 180 minutes of insulin infusion (Table 2). 
Mean plasma glucose varied between 91 ± 2 mg/dl and 108 ± 4 mg/dl 
(Figure 1). The mean coefficient of variation of steady-state 
plasma glucose was 11.9 ± 1.3% (Table 2). 
The amount of glucose metabolized (M) during the 3 hour study 
period of hyperinsulinemia averaged 15.49 ± 0.80 ,,*g/g gram body wt* 
min. The rate of glucose metabolism increased rapidly during the 
first 40 minutes of insulin infusion and remained constant there¬ 
after (Figure 1 and Table 3). 
In the control animals, the fasting plasma insulin averaged 
22 ± 1 y^U/rnl and glucose averaged 113 ± 3 mg/dl, and remained un¬ 
changed during the 180 minute saline infusion (Table 4). Plasma 
glucose concentrations were 10-15 mg/dl higher in control animals 
than in animals receiving insulin infusions (Table 4). 
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TABLE 3. Summary of Glucose Metabolism in 
Individual Animals During Insulin Clamp 
Glucose Metabolism Rate 
During Insulin Clamp 
_(-/*g/g/min.)_ 
Time (Min.) 
Subj ect 20-60 60-100 100-140 140-180 20-180 
1 14.89 13.44 13.78 11.88 13.50 
2 18.62 16.72 16.47 13.41 16.31 
3 14.53 15.98 17.70 17.13 16.34 
4 19.44 14.68 12 .75 10.55 14.36 
5 11.95 11.65 9.57 10.42 10.91 
6 8.57 7.81 9.22 8.21 8.45 
7 12.73 13.84 15.92 15.69 14.55 
8 11.36 11.44 12.88 10.79 11.62 
9 17.00 15.81 - 21.69 20.65 
10 14.13 14.91 15.04 14.48 14.64 
11 16.03 17.67 20.74 20.61 18.76 
12 15.28 15.16 15.96 16.48 15.71 
13 10.70 12.65 12.47 12.30 12.03 
14 9.69 11.41 8.65 9.13 9.72 
15 15.76 16.89 17.33 20.73 17.68 
16 17.43 18.59 20.06 22.25 19.58 
17 14.08 13.95 14.35 14.98 14.34 
18 15.73 18.46 19.90 20.04 18.53 
19 17.71 25.11 22.18 21.69 21.67 
20 19.53 20.79 20.92 20.80 20.53 
21 17.07 - - - - 
22 14.62 14.18 15.31 17.22 15.33 
Mean 14.64 15.12 15.34 15.44 15.49 
iSE ±0.98 ±0.79 ±1.01 ±1.00 ±0.80 
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TABLE 4. Characteristics of Insulin Infused 
and Saline Infused Animals* 
Body Wt. 
(g) 
Fasting 
Plasma 
Glucose 
(mg/dl) 
Steady- 
State 
Plasma 
Glucose** 
(mg/dl ) 
Fasting 
Plasma 
Insulin 
{/* U /ml) 
Saline Controls 
(n = 23) 
Insulin Infused 
Animals 
(n = 22) 
151 ±4 113 ± 3+ 109 ± 2^ 
161 ±4 100 ± 1 97 ± 2 
22 ± 1 
23 ± 2 
* All values are expressed as means ± SE. 
** Represents mean glucose concentrations from 
*** Represents mean insulin concentrations from 
20-180 
60-180 
minutes, 
minutes. 
+ P < 0.001 
+ + P < 0.005 
Steady- 
State 
Plasma 
Insulin*** 
(/‘U/ml) 
21 ± 1 
55 ± 2 
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Deoxyglucose Transport 
Basal 2-deoxyglucose (2-DOG) transport was increased by 42% 
in hyperinsulinemic animals (113 ± 7 pmoles/mg day wt • 15 min, 
n = 21) vs. controls (79 ± 5 pmoles/mg day wt • 15 min, n = 24) 
(p< 0.005). Basal transport in hyperinsulinemic animals (mean 
plasma insulin concentration = 2.2 ng/fril) was comparable to insulin- 
stimulated transport in soleus muscles from control animals incu¬ 
bated with 0.75 ng/ml of insulin in vitro. 
When soleus muscle from hyperinsulinemic animals was incubated 
in vitro with progressively increasing concentrations of insulin 
(Figure 2), insulin-stimulated 2-DOG transport was also increased. 
The insulin dose response curve in muscles from hyperinsulinemic 
animals was parallel but raised upwards. The increase in insulin- 
stimulated 2-DOG transport was statistically significant at insulin 
concentrations of 0.5 ng/ml (p<0.05) and 5 ng/ml (p<0.02). Al¬ 
though insulin-stimulated 2-DOG transport was also increased at 
insulin concentrations of 0.75, 1.0, and 10 ng/ml, this difference 
did not reach statistical significance. When data from the 5 ng/ml 
and 10 ng/ml points were pooled to represent a maximally-stimulated 
value, this difference was found to be statistically significant 
(p< 0.05). Dose response curves in muscles from hyperinsulinemic 
and control animals were similar when basal 2-DOG transport was 
subtracted from insulin-stimulated 2-DOG transport (Figure 3). 
Epinephrine levels prior to sacrifice were somewhat elevated 
in hyperinsulinemic animals (197 ± 42 pg/ml) vs. controls (100 ± 23 
pg/ml). However, this difference was not statistically significant 
due to the large amount of scatter in both groups. Moreover, there 
was no correlation between epinephrine levels and basal 2-DOG 
transport (r = -0.20). 
- 
30 
(NIWgi/0VN/S3“lOWd) Id OdSNVdl 0OQ-2 
3 a) 
toO 3 
•H *H ft, 3 
cn 
3 
o 
•U M-l O 
3 0 0 
o 
ft CO O 
cn cu 3 i—I \> 
3 O v 
3 S CU 
4-J (ft, -X 

i4
o 
r 
31 
X 
\ 
\ 
\ 
\ 
\ 
\ 
\ 
\ 
00 
- C"- 
- t9 
^*r! 
. ^ 
ID 2 
N 
o 
z: 
_j 
Z) 
un 
Z 
rO — 
-* C\J 
o 
CM 
O 
00 
o 
-vT 
O 
(N IWSI/9W/S3~IOVNd)ldQdSNVUl 000-Z 
a Bivinmis-NiinsNi 
F
ig
u
re
 
3
. 
In
s
u
li
n
-s
ti
m
u
la
te
d
 
2
-d
e
o
x
y
g
lu
c
o
se
 
(2
-D
O
G
) 
tr
a
n
s
p
o
rt
 
in
 
v
it
ro
 
in
 
r
a
t 
s
o
le
u
s 
m
u
s
c
le
s 
fr
o
m
 
a
n
im
a
ls
 
r
e
c
e
iv
in
g
 
in
s
u
li
n
 
(
A
-
A
)
 
o
r
 
s
a
li
n
e
 
(
#
-
“
•
)
 
in
fu
s
io
n
s
. 
B
a
sa
l 
tr
a
n
s
p
o
rt
, 
in
 
th
e
 
a
b
se
n
c
e
 
o
f 
a
d
d
ed
 
in
 
v
it
ro
 
in
s
u
li
n
, 
h
a
s 
b
e
e
n
 
s
u
b
tr
a
c
te
d
 
fr
o
m
 
a
ll
 
v
a
lu
e
s
. 
V
a
lu
e
s 
r
e
p
re
s
e
n
t 
in
s
u
li
n
-s
ti
m
u
la
te
d
 
tr
a
n
s
p
o
rt
 
a
b
o
v
e 
b
a
s
a
l.
 
A
ll
 
v
a
lu
e
s 
a
r
e
 
e
x
p
re
ss
e
d
 
a
s
 
m
e
a
n
 
±
 
S
E
. 
*
p 
<
 
0
.0
5
. 
o 
' 
v 
o 
* 
t/V . : 
32 
Discussion 
The present studies have examined the effects of prolonged 
(3 hours) hyperinsulinemia on in vivo glucose metabolism and in 
vitro glucose transport in rat soleus muscle. Modification of the 
euglycemic insulin clamp technique (23) to the rat has enabled us 
to perform these studies under conditions where changes in plasma 
glucose concentration are prevented. 
Studies by Olefsky et. al. (21, 22) have suggested that chronic 
in vivo hyperinsulinemia leads to an increase in basal and maxi¬ 
mally insulin-stimulated glucose transport in rat adipocytes. How¬ 
ever, earlier studies (19) by the same group failed to demonstrate 
this effect in a similar model. In these earlier studies, an in¬ 
crease in glucose transport may have been prevented by the failure 
to maintain euglycemia in these hyperinsulinemic animals. Both 
changes in plasma glucose and counter-regulatory hormones have been 
shown to effect tissue glucose metabolism (64-70). Alternatively, 
an increase in glucose transport may have already been present in 
the control animals, which were both hyperinsulinemic (29 ± 3/^U/ml) 
and relatively hyperglycemic (152 ± 5 mg/dl). An increase in 
glucose transport in the control group may have masked the differ¬ 
ence between the two groups. 
The present experiments demonstrate an increase in skeletal 
muscle glucose transport following 3 hours of physiologic hyper¬ 
insulinemia in vivo. This increase in glucose transport was ob¬ 
served both in the basal state and after stimulation with, insulin 
in vitro (Figure 2). Similarly, an increase in maximal insulin- 
stimulated glucose transport was also observed, although data from 
the 5 ng/ml and 10 ng/ml points had to be pooled to establish 
' 
- 
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statistical significance. On the other hand, insulin stimulation 
of glucose transport above basal was unchanged (Figure 3). Thus, 
in vivo hyperinsulinemia causes an activation of basal glucose 
transport but appears to have no effect on the ability of the 
soleus muscle to respond to additional insulin in vitro. 
It could be argued than a carry over of insulin from the in 
vivo insulin clamp study into the in vitro transport assay would 
account for an increase in basal glucose transport. This possib¬ 
ility seems unlikely for the following reasons. 1) Several steps 
are involved which would dilute out insulin from the in vivo study, 
including washing the muscles, a 15 minute preincubation, and a 3 
hour incubation in insulin free buffer prior to assay. Previous 
studies have also shown that washing procedures are effective in 
removing in vivo insulin which has stuck to the plasma membrane 
before assaying for insulin binding (71). 2) Physiologically, 
insulin carried over from the in vivo study would be additive 
with insulin added during the in vitro study and would shift the 
dose response curve to the left. However, maximally stimulated 
glucose transport would remain the same and this was not the case. 
We also considered the possibility that an increase in basal 
and insulin-stimulated glucose transport could be attributed to 
the ability of insulin in the plasma during the insulin clamp study 
to have access to a compartment which was not accessible during in 
vitro exposure to insulin. This seems unlikely since muscles were 
incubated with insulin for 3 hours in vitro and diffusion of insulin 
into rat soleus muscle does not appear tc be rate-limiting under 
these conditions (26, 31). One would expect equilibration of buffer 
and interstitial insulin concentrations during the 3 hour incubation. 
* 
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Persistent activation of the glucose transport system by in 
vivo exposure to insulin appears to be the most likely explan¬ 
ation for the increase in basal 2-DOG transport observed in vitro. 
Basal transport 3 hours after exposure to 55y*U/ml (2.2 ng/ml) of 
insulin in vivo was 40% greater than in control animals, but was 
less than that observed in muscles from control animals exposed 
to an equivalent concentration of insulin (2.2 ng/ml) in vitro. 
This finding may reflect a time-dependent deactivation of insulin- 
stimulated glucose transport. Basal transport immediately following 
exposure to insulin in vivo may in fact have been similar to trans¬ 
port observed with an equivalent concentration of insulin in vivo. 
In this regard, the time course of deactivation of insulin- 
stimulated glucose transport has been studied in the rat adipocyte 
following a 60 minute in vitro exposure to 1 ng/ml of insulin (36). 
Deactivation of insulin-stimulated 3-0-MG transport had a t% of 43 
minutes at 37°C and 73 minutes at 24°C in the presence of 1 mM 
glucose. Persistant activation of glucose transport continued 
despite a reversal of insulin receptor binding (36). Furthermore, 
insulin-stimulation of glucose transport persisted unchanged when 
deactivation was studied for 2 hours in the absence of both insulin 
and glucose (36). Thus, these results are consistent with the 
present experiments which demonstrate a persistent activation of 
2-DOG transport in rat soleus muscles 3 hours after in vivo ex¬ 
posure to insulin. 
In addition to an increase in basal 2-DOG transport, insulin- 
stimulated 2-DOG transport was also increased following 3 hours 
of in vivo hyperinsulinemia. An increase in maximal stimulated 
transport must represent activation or recruitment of new transport 
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units from a compartment not accessible to a 3 hour exposure to 
insulin in vitro. If in vivo exposure to insulin caused activa¬ 
tion of transport units from a fixed compartment, then further in 
vitro insulin-stimulation would not have resulted in the apparent 
increase in maximal transport observed in these studies. 
The ability of combined in vivo hyperinsulinemia and in vitro 
insulin to produce a greater activation of glucose transport than 
normoinsulinemia in vivo plus in vitro insulin could have several 
explanations. This effect may be time-dependent and require 6 
hours of exposure to increased insulin concentrations, or alter¬ 
natively an additional 3 hours may be required following the 3 
hour in vivo exposure to insulin for the enhancing effect on glucose 
transport to develop. If either of these explanations were the case, 
one would expect that 6 hours of exposure to either in vivo or 
in vitro insulin alone should produce a similar effect. While 
these possibilities cannot be excluded, we think that it is most 
likely that some effect of in vivo as opposed to in vitro exposure 
to insulin contributes to the observed increase in 2-DOG transport. 
Perhaps the acceleration of glucose metabolism achieved during in 
vivo hyperinsulinemia is involved in this effect. 
We also considered the possibility that other in vivo factors 
unrelated to insulin might have an effect which persists through 
the 3 hour in vitro incubation prior to assay of glucose transport. 
Since the plasma glucose concentration was maintained constant 
at the basal level, it is unlikely that changes in glucose con¬ 
centration could have contributed to the increase in 2-DOG trans¬ 
port observed. Similarly, although fasting levels of plasma glu¬ 
cose were slightly lower in hyperinsulinemic animals (100 vs 113 mg/dl) 
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we would not expect that this small difference in plasma glucose 
would account for the increase in 2-DOG transport observed, es¬ 
pecially since lower plasma glucose in the normal range has been 
correlated with a lower rate of in vivo glucose metabolism. (R. A. 
DeFronzo, personal communication). It is also unlikely that 
changes in counter-regulatory hormones contributed to the increase 
in 2-DOG transport observed since plasma epinephrine levels were 
not significantly elevated in hyperinsulinemic animals and there 
was no correlation between epinephrine levels and basal transport. 
Furthermore, increases in counter-regulatory hormones, e.g., ep¬ 
inephrine, would have been expected to have an opposite effect, 
namely a decrease in cellular glucose transport, based on previous 
in vitro and in vivo studies (64-70). 
Skeletal muscle has been shown to be the principle tissue 
responsible for glucose utilization during euglycemic hyperinsul- 
emia (23, 72). In the present study, an increase in insulin- 
stimulated 2-DOG transport by soleus muscle was documented following 
a combined exposure to 3 hours each of in vivo and in vitro insulin. 
Nonetheless, the rate of glucose metabolism during the 140-180 min¬ 
ute period of the insulin clamp study (15.44 g/g/min.) was sim¬ 
ilar to that observed during the 20-60 minute period (14.64/^g/g/min.). 
Several explanations may account for this "apparent discrepancy". 
The failure to observe an increase in glucose metabolism 
during the 3 hour insulin clamp study may indicate that the in¬ 
crease in glucose transport is time-dependent and a 6 hour com¬ 
bined in vivo and in vitro exposure to insulin is required to 
produce the increase in 2-DOG transport observed. Alternatively, 
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an increase in glucose metabolism in vivo may have been prevented 
by other changes which led to a counter-balancing decrease in 
peripheral glucose utilization, but whose effects were dissipated 
during the 3 hour incubation period prior to assay of 2-DOG trans¬ 
port. In this regard, a concomitant reversible decrease in re¬ 
ceptor binding could off-set an increase in glucose transport and 
prevent an increase in in vivo glucose utilization. Although 
insulin binding to soleus muscle was not examined in the present 
study, decreased insulin binding to monocytes has been demonstrated 
by Soman and DeFronzo (20) following a 3 hour euglycemic insulin 
clamp at 100 ^ U/ml in man. In addition, regeneration of insulin 
receptor binding in adipocytes within 3 hours after chronic in 
vivo hyperinsulinemia has been demonstrated by Kobayaski and 
Olefsky (19). If these results are applicable to soleus muscle, 
then a decrease in insulin receptor binding may have counter¬ 
balanced an increase in the glucose transport system and prevented 
an increase in in vivo glucose utilization. Alternatively, an 
increase in plasma epinephrine during the last period of the insulin 
clamp could prevent an increase in glucose metabolism, but have 
been dissipated during the 3 hour incubation prior to assay of 
2-DOG transport. This seems unlikely since epinephrine levels 
were not significantly elevated and there was no correlation between 
epinephrine levels at sacrifice and the rate of glucose metabolism 
during the final period of the insulin clamp study. 
Recently, Cushman et. al. (41, 42) have proposed that insulin 
activation of glucose transport involves the recruitment of glu¬ 
cose transport units from an intracellular microsomal compartment 
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into the plasma membrane. Based on the present experiments, an 
extension of this model can be proposed. Prolonged in vivo insulin 
stimulation may lead to the recruitment of transport units from 
an intracellular pool and the persistent activation of these units 
in the plasma membrane, and a subsequent regeneration of the micro¬ 
somal pool, so that acute insulin-stimulation will again elicit 
a full augmentation of glucose transport and the additive effect 
will produce an increase in maximal glucose transport. The time- 
dependence of the increase in maximal glucose transport postulated 
in this discussion may in fact represent the synthesis of new 
glucose transport units. 
In conclusion: in vivo hyperinsulinemia achieved by the 
euglycemic insulin clamp technique results in 1) prolonged activ¬ 
ation of glucose transport in skeletal muscle manifest as an in¬ 
crease in basal transport 3 hours after in vivo exposure to insulin 
and 2) an augmentation of insulin-stimulated glucose transport. 
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